Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial

MLA

Bistervels, Ingrid M., et al. “Intermediate-Dose versus Low-Dose Low-Molecular-Weight Heparin in Pregnant and Post-Partum Women with a History of Venous Thromboembolism (Highlow Study): An Open-Label, Multicentre, Randomised, Controlled Trial.” The Lancet, vol. 400, no. 10365, Nov. 2022, pp. 1777–87. EBSCOhost, https://doi.org/10.1016/S0140-6736(22)02128-6.

APA

Bistervels, I. M., Buchmüller, A., Wiegers, H. M. G., Ní Áinle, F., Tardy, B., Donnelly, J., Verhamme, P., Jacobsen, A. F., Hansen, A. T., Rodger, M. A., DeSancho, M. T., Shmakov, R. G., van Es, N., Prins, M. H., Chauleur, C., Middeldorp, S., van den Akker, E. S., Bekker, M. N., van Bemmel, T., … Zelis, M. (2022). Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial. The Lancet, 400(10365), 1777–1787. https://doi.org/10.1016/S0140-6736(22)02128-6

Chicago

Bistervels, Ingrid M, Andrea Buchmüller, Hanke M G Wiegers, Fionnuala Ní Áinle, Bernard Tardy, Jennifer Donnelly, Peter Verhamme, et al. 2022. “Intermediate-Dose versus Low-Dose Low-Molecular-Weight Heparin in Pregnant and Post-Partum Women with a History of Venous Thromboembolism (Highlow Study): An Open-Label, Multicentre, Randomised, Controlled Trial.” The Lancet 400 (10365): 1777–87. doi:10.1016/S0140-6736(22)02128-6.